139 related articles for article (PubMed ID: 19468197)
1. Medullary thyroid cancer: molecular biology and novel molecular therapies.
Cakir M; Grossman AB
Neuroendocrinology; 2009; 90(4):323-48. PubMed ID: 19468197
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
Cerrato A; De Falco V; Santoro M
J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
[TBL] [Abstract][Full Text] [Related]
3. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
4. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
5. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
6. Management of medullary thyroid cancer.
Ball DW
Minerva Endocrinol; 2011 Mar; 36(1):87-98. PubMed ID: 21460789
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
8. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
9. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
10. Medullary thyroid cancer: therapeutic targets and molecular markers.
Ball DW
Curr Opin Oncol; 2007 Jan; 19(1):18-23. PubMed ID: 17133107
[TBL] [Abstract][Full Text] [Related]
11. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
12. Molecular advances in medullary thyroid cancer diagnostics.
Hubner RA; Houlston RS
Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
[TBL] [Abstract][Full Text] [Related]
13. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
14. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid carcinoma.
Leboulleux S; Baudin E; Travagli JP; Schlumberger M
Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
[TBL] [Abstract][Full Text] [Related]
16. Current management of medullary thyroid cancer.
Sippel RS; Kunnimalaiyaan M; Chen H
Oncologist; 2008 May; 13(5):539-47. PubMed ID: 18515739
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic approaches to treat medullary thyroid carcinoma.
Schlumberger M; Carlomagno F; Baudin E; Bidart JM; Santoro M
Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):22-32. PubMed ID: 18084343
[TBL] [Abstract][Full Text] [Related]
18. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.
Skinner MA; Safford SD; Freemerman AJ
Anticancer Res; 2003; 23(5A):3601-6. PubMed ID: 14666655
[TBL] [Abstract][Full Text] [Related]
19. Medullary thyroid carcinoma: surgical treatment advances.
Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
[TBL] [Abstract][Full Text] [Related]
20. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
